[
    [
        {
            "time": "2018-06-25",
            "original_text": "Insider Buying Report: DOVA, ABBV",
            "features": {
                "keywords": [
                    "Insider Buying",
                    "DOVA",
                    "ABBV"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Insider Buying Report: DOVA, ABBV",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-06-25",
            "original_text": "The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Procter & Gamble",
                    "AbbVie",
                    "IBM",
                    "McDonald's",
                    "General Electric"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "consumer goods",
                    "pharmaceuticals",
                    "technology",
                    "food service",
                    "industrial"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-25",
            "original_text": "IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer",
            "features": {
                "keywords": [
                    "IMBRUVICA",
                    "FDA",
                    "Supplemental New Drug Application",
                    "Waldenström's Macroglobulinemia"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-25",
            "original_text": "The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Procter & Gamble",
                    "AbbVie",
                    "IBM",
                    "McDonald's",
                    "General Electric"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "consumer goods",
                    "pharmaceuticals",
                    "technology",
                    "food service",
                    "industrial"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-25",
            "original_text": "AbbVie and Calibr announce collaboration for next generation T-cell therapies",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Calibr",
                    "collaboration",
                    "T-cell therapies"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie and Calibr announce collaboration for next generation T-cell therapies",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]